Moreover, the stigma surrounding obesity disproportionately affects lower-income individuals, who are often blamed for their ...

Fat-busting wonder drugs loved by celebs are taking their toll in the bedroom by ruining people’s sex lives. Men are ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...

Novo Nordisk shares (DK:NOVO.B) (NVO) rallied 4% in early Copenhagen trade. Ozempic's 33.85 billion kroner of sales compared to analyst expectations of 33.34 billion kroner, and Wegovy's 19.87 billion ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...